Predpokladaný rast EPS Q/Q spoločnosti Inhibrx
Aká je hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Inhibrx?
Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Inhibrx, Inc. je 43.64%
Aká je definícia metriky Predpokladaný rast EPS Q/Q?
Očakávaný rast EPS (Estimated quarterly EPS growth rate) z roka na rok je predpokladaný rast EPS spoločnosti za ďaľší kvartál v porovnaní s výsledkami z minulého kvartálu.
The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Predpokladaný rast EPS Q/Q spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx
Čomu sa venuje spoločnosť Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou predpokladaný rast eps q/q podobnou spoločnosti Inhibrx
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti SNC-Lavalin je 43.48%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Ideal Power Inc je 43.48%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Heritage Commerce je 43.48%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Herc Inc je 43.50%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti RCI Industries & Technologies je 43.61%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti ArcBest Corp je 43.63%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Inhibrx je 43.64%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Viking Therapeutics Inc je 43.75%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti BioCardia je 43.75%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti BioCardia je 43.75%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Keyera je 43.75%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti ChemoCentryx Inc je 43.75%
- Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Great Southern je 43.86%